PMID- 34984861 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20220729 IS - 1097-0339 (Electronic) IS - 8755-1039 (Print) IS - 1097-0339 (Linking) VI - 50 IP - 3 DP - 2022 Mar TI - Differential diagnosis of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma by cytological analysis. PG - 112-122 LID - 10.1002/dc.24928 [doi] AB - BACKGROUND: Adipocytic tumors are the most common soft tissue tumors, with lipomas and atypical lipomatous tumor/well-differentiated liposarcomas (ALT/WDL), which comprise most cases. Preoperative differential diagnosis of lipoma or ALT/WDL can provide important information for decisions regarding treatment. We evaluated the cytological findings of 20 cases of lipoma and ALT/WDL. METHODS: Fluorescence in situ hybridization (FISH) was performed on formalin-fixed paraffin-embedded specimens (FFPE) to examine mouse double minute 2 homolog (MDM2) amplification in all cases. Tissue samples were collected from the center of the surgical materials, stained with Pap, and evaluated for 12 cytological parameters by six cytotechnologists. RESULTS: The findings regarding large atypical cells, multinucleated cells, and nuclear pleomorphism were highly concordant among the cytotechnologists and were associated with MDM2 amplification. Large atypical cells, considered a highly specific feature of ALT/WDL, were not observed in lipoma cases. However, the sensitivity of the large atypical cell findings was not high (67%); therefore, comprehensive evaluation of multinucleated cells and pleomorphism is crucial for predicting ALT/WDL diagnosis. FISH of MDM2 on Pap-stained specimens was performed in four cases. In two, the results were similar to those of MDM2 FISH performed on FFPE sections and were reproducible, whereas in the other two, the signal could not be evaluated because of the strong background coloration. CONCLUSIONS: Cytology specimens may be useful for the preoperative diagnosis of adipocytic tumors, particularly if the FISH conditions for Pap-stained specimens and the detection accuracy of MDM2 amplification can be improved. CI - (c) 2022 The Authors. Diagnostic Cytopathology published by Wiley Periodicals LLC. FAU - Sugiyama, Kana AU - Sugiyama K AD - Department of Clinical Laboratory, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. FAU - Washimi, Kota AU - Washimi K AUID- ORCID: 0000-0001-6353-776X AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. FAU - Sato, Shinya AU - Sato S AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. AD - Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan. FAU - Hiruma, Toru AU - Hiruma T AD - Department of Musculoskeletal Tumor Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. FAU - Sakai, Mai AU - Sakai M AD - Department of Clinical Laboratory, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. FAU - Okubo, Yoichiro AU - Okubo Y AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. FAU - Miyagi, Yohei AU - Miyagi Y AD - Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan. FAU - Yokose, Tomoyuki AU - Yokose T AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. LA - eng GR - JP 20K16210/Grant-in-aid for Scientific Research/ GR - 2020-12/Kanagawa Cancer Center Hospital-Research Institute Joint Study/ PT - Journal Article DEP - 20220104 PL - United States TA - Diagn Cytopathol JT - Diagnostic cytopathology JID - 8506895 RN - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2) SB - IM MH - Animals MH - Diagnosis, Differential MH - Humans MH - In Situ Hybridization, Fluorescence/methods MH - *Lipoma/diagnosis/genetics/pathology MH - *Liposarcoma/diagnosis/genetics/pathology MH - Mice MH - Proto-Oncogene Proteins c-mdm2/genetics PMC - PMC9305447 OTO - NOTNLM OT - MDM2 OT - cytology OT - fluorescence in situ hybridization OT - lipoma OT - well-differentiated liposarcoma COIS- No conflict of interest declared. EDAT- 2022/01/06 06:00 MHDA- 2022/04/05 06:00 PMCR- 2022/07/22 CRDT- 2022/01/05 06:22 PHST- 2021/12/23 00:00 [revised] PHST- 2021/11/02 00:00 [received] PHST- 2021/12/26 00:00 [accepted] PHST- 2022/01/06 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2022/01/05 06:22 [entrez] PHST- 2022/07/22 00:00 [pmc-release] AID - DC24928 [pii] AID - 10.1002/dc.24928 [doi] PST - ppublish SO - Diagn Cytopathol. 2022 Mar;50(3):112-122. doi: 10.1002/dc.24928. Epub 2022 Jan 4.